Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
Abstract Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. Methods: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. Results: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (p<0.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (p<0.001 and p<0.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2–31.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%). Conclusion: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. Trial registration NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 17. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dam, Koos van [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2272601/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA038375923 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA038375923 | ||
| 003 | DE-627 | ||
| 005 | 20231205145744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230110s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2272601/v1 |2 doi | |
| 035 | |a (DE-627)XRA038375923 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2272601/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dam, Koos van |e verfasserin |0 (orcid)0000-0002-2602-4364 |4 aut | |
| 245 | 1 | 0 | |a Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. Methods: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. Results: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (p<0.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (p<0.001 and p<0.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2–31.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%). Conclusion: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. Trial registration NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Volkers, Adriaan |4 aut | |
| 700 | 1 | |a Wieske, Luuk |4 aut | |
| 700 | 1 | |a Stalman, Eileen |4 aut | |
| 700 | 1 | |a Kummer, Laura |4 aut | |
| 700 | 1 | |a kempen, Zoe van |4 aut | |
| 700 | 1 | |a Killestein, Joep |4 aut | |
| 700 | 1 | |a Tas, Sander |4 aut | |
| 700 | 1 | |a Boekel, Laura |4 aut | |
| 700 | 1 | |a Wolbink, Gertjan |4 aut | |
| 700 | 1 | |a Kooi, Anneke van der |4 aut | |
| 700 | 1 | |a Raaphorst, Joost |4 aut | |
| 700 | 1 | |a Takkenberg, Bart |4 aut | |
| 700 | 1 | |a D'Haens, Geert |4 aut | |
| 700 | 1 | |a Spuls, Phyllis |4 aut | |
| 700 | 1 | |a Bekkenk, Marcel |4 aut | |
| 700 | 1 | |a Musters, Annelie |4 aut | |
| 700 | 1 | |a Post, Nicoline |4 aut | |
| 700 | 1 | |a Bosma, Angela |4 aut | |
| 700 | 1 | |a Hilhorst, Marc |4 aut | |
| 700 | 1 | |a Vegting, Yosta |4 aut | |
| 700 | 1 | |a Bemelman, Frederike |4 aut | |
| 700 | 1 | |a Voskuyl, Alexandre |4 aut | |
| 700 | 1 | |a Broens, Bo |4 aut | |
| 700 | 1 | |a Sanchez, Agner Parra |4 aut | |
| 700 | 1 | |a Els, Cecile van |4 aut | |
| 700 | 1 | |a de Wit, Jelle |4 aut | |
| 700 | 1 | |a Rutgers, Abraham |4 aut | |
| 700 | 1 | |a de Leeuw, Karina |4 aut | |
| 700 | 1 | |a Horvath, Barbara |4 aut | |
| 700 | 1 | |a Verschuuren, Jan |4 aut | |
| 700 | 1 | |a Ruiter, Annabel |4 aut | |
| 700 | 1 | |a Ouwerkerk, Lotte van |4 aut | |
| 700 | 1 | |a Woude, Diane van der |4 aut | |
| 700 | 1 | |a Allaart, Renee |4 aut | |
| 700 | 1 | |a Teng, Onno |4 aut | |
| 700 | 1 | |a Paassen, Pieter van |4 aut | |
| 700 | 1 | |a Busch, Matthias |4 aut | |
| 700 | 1 | |a Jallah, Papay |4 aut | |
| 700 | 1 | |a Brusse, Esther |4 aut | |
| 700 | 1 | |a Doorn, Pieter van |4 aut | |
| 700 | 1 | |a Baars, Adaja |4 aut | |
| 700 | 1 | |a Hijnen, DirkJan |4 aut | |
| 700 | 1 | |a Schreurs, Corine |4 aut | |
| 700 | 1 | |a Pol, Ludo van der |4 aut | |
| 700 | 1 | |a Goedee, Stephan |4 aut | |
| 700 | 1 | |a Steenhuis, Maurice |4 aut | |
| 700 | 1 | |a Keijzer, Sofie |4 aut | |
| 700 | 1 | |a Keijser, Jim |4 aut | |
| 700 | 1 | |a Cristianawati, Olvi |4 aut | |
| 700 | 1 | |a Brinke, Anja ten |4 aut | |
| 700 | 1 | |a Verstegen, Niels |4 aut | |
| 700 | 1 | |a Ham, Marieke van |4 aut | |
| 700 | 1 | |a Rispens, Theo |4 aut | |
| 700 | 1 | |a Kuijpers, Taco |4 aut | |
| 700 | 1 | |a Lowenberg, Mark |4 aut | |
| 700 | 1 | |a Eftimov, Filip |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 17. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-023-08298-6 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2272601/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 10 | ||